Claims
- 1. A method for treating ocular hypertension or glaucoma in a subject's eye which comprises contacting the surface of the eye with a composition comprising a beta-adrenergic blocking agent and an ester of prostaglandin F.sub.2.alpha. or a derivative of an ester of prostaglandin F.sub.2.alpha. in an ophthalmically compatible carrier, the amounts in the mixture being between about 5 .mu.g and about 500 .mu.g and between about 0.01 .mu.g and about 1000 .mu.g, respectively, and being such as to be effective so as to reduce the intraocular pressure of the eye and maintain such reduced pressure.
- 2. The method of claim 1, wherein the beta-adrenergic blocking agent is timolol maleate.
- 3. The method of claim 1, wherein the beta-adrenergic blocking agent is betaxolol hydrochloride.
- 4. The method of claim 1, wherein the beta-adrenergic blocking agent is levobunolol hydrochloride.
- 5. The method of claim 1, wherein the PGF.sub.2.alpha. derivative is PGF.sub.2.alpha. -1-isopropyl ester.
- 6. A method of claim 1, wherein the prostaglandin F.sub.2.alpha. or derivative of prostaglandin F.sub.2.alpha. is present in the mixture in an amount between about 0.1 .mu.g and about 500 .mu.g.
- 7. A method of claim 1, wherein the ophthalmically compatible carrier comprises an aqueous solution.
- 8. A method of claim 7, wherein the aqueous solution is a saline solution containing an ophthalmically compatible preservative, a surfactant, and an agent, such as a soluble polymer, to increase the viscosity of the solution.
- 9. A method of claim 1, wherein the mixture is dissolved in the ophthalmically compatible carrier.
- 10. A method of claim 1, wherein the contacting is effected periodically.
- 11. A method of claim 10, wherein the periodic contacting is effected at least daily.
- 12. A method of claim 1, wherein the subject is a primate.
- 13. A composition for the topical treatment of ocular hypertension or glaucoma comprising a mixture of a beta-adrenergic blocking agent and an ester of prostaglandin F.sub.2.alpha. or a derivative of an ester of prostaglandin F.sub.2.alpha. in an ophthalmically compatible carrier and the amounts in the mixture being between 5 .mu.g and about 500 .mu.g and between about 0.01 .mu.g and about 1000 .mu.g, respectively, being such as to be effective so as to reduce the intraocular pressure of the eye and maintain such reduced pressure.
- 14. A composition of claim 13, wherein the beta-adrenergic blocking agent is timolol maleate.
- 15. A composition of claim 13, wherein the beta-adrenergic blocking agent is betaxolol hydrochloride.
- 16. A composition of claim 13, wherein the beta-adrenergic blocking agent is levobunolol hydrochloride.
- 17. A composition of claim 13, wherein the PGF.sub.2.alpha. derivative is PGF.sub.2.alpha.`- 1-isopropyl ester.
- 18. A composition of claim 13, wherein the prostaglandin or prostaglandin derivative is present in the mixture in an amount between about 0.1 .mu.g and about 50 .mu.g.
- 19. A composition of claim 13, wherein the ophthalmically compatible carrier comprises an aqueous solution.
- 20. A composition of claim 19, wherein the aqueous solution is a saline solution containing an ophthalmically compatible preservative, a surfactant, and an agent, such as a soluble polymer, to increase the viscosity of the solution.
- 21. A composition of claim 13, wherein the mixture is dissolved in the ophthalmically compatible carrier.
- 22. A method for treating ocular hypertension or glaucoma in a primate subject's eye which comprises contacting the surface of the eye with a composition comprising an effective intraocular pressure reducing amount of a mixture of levobunolol hydrochloride and PGF.sub.2.alpha.`- 1-isopropyl ester dissolved in an ophthalmically compatible carrier, so as to reduce the intraocular pressure of the eye and maintain such reduced intraocular pressure.
- 23. A composition for the topical treatment of ocular hypertension or glaucoma comprising an effective intraocular pressure reducing amount of a mixture of levobunolol hydrochloride and PGF.sub.2.alpha.`- 1-isopropyl ester dissolved in an ophthalmically compatible carrier.
Parent Case Info
This application is a continuation of U.S. Ser. No. 034,484, filed Apr. 3, 1987, now abandoned.
BACKGROUND OF THE INVENTION
The invention described herein was made with government support under grant number EY00333 from the National Eye Institute, National Institutes of Health, Department of Health and Human Services. The U.S. Government has certain rights in this invention.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4474751 |
Haslam et al. |
Oct 1984 |
|
4599353 |
Bito |
Jul 1986 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
34484 |
Apr 1987 |
|